(Q39662895)

English

Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: Synthesis and biological evaluation

scientific article published on August 6, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: synthesis and biological evaluation (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: Synthesis and biological evaluation (English)

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

positron emission tomography

1 reference

based on heuristic

inferred from title

Positron-emission tomography

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20797871

2 July 2024

Federica Pisaneschi

1

object named as

Federica Pisaneschi

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20797871

2 July 2024

Edward G Robins

5

object named as

Edward Robins

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20797871

2 July 2024

7

object named as

Graham Smith

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20797871

2 July 2024

9

object named as

Eric O. Aboagye

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20797871

2 July 2024

author name string

Quang-De Nguyen

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Elham Shamsaei

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Matthias Glaser

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Maciej Kaliszczak

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Alan C. Spivey

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20797871

2 July 2024

language of work or name

0 references

publication date

6 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

full work available at URL

http://spiral.imperial.ac.uk/bitstream/10044/1/9997/4/Spivey%2c%20A%20-%20Development%20of%20a%20new%20EGFR.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20797871

2 July 2024

https://api.elsevier.com/content/article/PII:S0968089610007418?httpAccept=text/xml

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

https://api.elsevier.com/content/article/PII:S0968089610007418?httpAccept=text/plain

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Bioorganic & Medicinal Chemistry

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

6634-6645

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Signal transduction and oncogenesis by ErbB/HER receptors

1

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

The epidermal growth factor receptor family

2

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Epidermal growth factor-related peptides and their receptors in human malignancies

3

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?

4

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

The epidermal growth factor receptor and its inhibition in cancer therapy

5

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer

7

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy

8

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

9

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

10

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

11

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer

12

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.

13

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.

14

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines

15

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase.

18

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes.

19

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug.

20

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors

21

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors

22

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety--an EGFR putative irreversible inhibitor

23

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

A fully automated two-step synthesis of an (18)F-labelled tyrosine kinase inhibitor for EGFR kinase activity imaging in tumors

25

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

26

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors

27

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Combinatorial chemoprevention of intestinal neoplasia

28

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the hum

29

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics

30

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

31

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

1,3-Dipolar Cycloadditions. Past and Future

33

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides

35

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Click chemistry, a powerful tool for pharmaceutical sciences

36

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

"Click labeling" with 2-[18f]fluoroethylazide for positron emission tomography.

38

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

One-pot synthesis of 1,4-disubstituted 1,2,3-triazoles from in situ generated azides

39

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor

40

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture

41

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Guidelines for the welfare and use of animals in cancer research

42

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors

43

1 reference

10.1016/J.BMC.2010.08.004

https://api.crossref.org/works/10.1016/J.BMC.2010.08.004

2 July 2024

Identifiers

10.1016/J.BMC.2010.08.004

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39662895&oldid=2193812481"